Barely Significant
← all excerpts

Low serum neopterin early indicates durable benefits of atezolizumab and pembrolizumab therapy in advanced lung cancer.

Sci Rep · 2025 · PMC12003904 · PMID 40240475

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

a clear trendp = 0.05actually significant
However, a clear trend toward longer survival with low-NEO status was noticed, especially in the PEMBRO subgroup (27.8 vs. 16.2 months, p = 0.05, Fig.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.